Xilio Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $59.2M
- Price
- $9.00
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.21%
- Volume
- 6.2K
About
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Quick stats
Shares outstanding6.6M
Computed float6.3M
Float / shares95.0%
Cash runway (months)25.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001840233
Websitehttps://www.xiliotx.com
AI Summary
AI-generated1/11
minorneutralboard change
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics granted inducement stock options on 205,895 aggregate shares under its 2022 Inducement Stock Incentive Plan, effective October 1, 2026.
The grants include options on 100,895 shares to two new employees and options on 105,000 shares to newly appointed Chief Medical Officer Yariv Houvras, M.D., Ph.D.
Options carry a $8.91 exercise price (the October 1 close), a ten-year term, and standard 25%-at-one-year plus 36-month vesting, per Nasdaq Rule 5635(c)(4).